Investment Week hosted our 14th annual Investment Company of the Year Awards at a glittering ceremony in London last night.
With RDR only a matter of weeks away, the investment company sector finds itself at the dawn of a new era.
It is therefore encouraging that a growing number of boards and management groups have done a huge amount of work to improve the transparency of communication with existing shareholders and also broaden appeal to newer investors. Many of these companies were rewarded for their efforts at last night’s awards.
External members of the judging panel were Simon Moore at Bestinvest, Simon Elliott at Winterflood, Midas’ Nick Greenwood, independent consultant James Carthew, Ben Yearsley and Stephen Peters from Charles Stanley and a new panellist this year, Peter Bristowe from Edison Research.
Award winners revealed
Performance data for the awards was provided by the AIC, Morningstar and FE Trustnet.
Congratulations to all our winners and finalists.
W: Aberdeen Asian Smaller Cos
Aberdeen All Asia
Aberdeen New Dawn
Schroder Asia Pacific
Commodity & Resources
W: City Natural Resources High Yield
HC: BlackRock World Mining
Golden Prospect Precious Metals
W: Utilico Emerging Markets
BlackRock Latin America
J.P. Morgan Emerging Markets
Templeton Emerging Markets
W: Jupiter European Opps
HC: BlackRock Greater Europe
Fidelity European Values
Henderson European Focus
Montanaro European Smaller Companies
W: Lindsell Train
F&C Global Smaller Companies
Mid Wynd International
Boussard & Gavaudan Holding (£)
Acencia Debt Strategy
BH Macro (£)
Bluecrest Allblue (£)
Third Point Offshore Investors (Chpt 14) £
W: Aberdeen Asian Income
Middlefield Canadian Income
Schroder Oriental Income
Securities Trust of Scotland
W: Electra Private Equity
Harbourvest Global Private Equity
Henderson Private Equity
Pantheon International Participations
Princess Private Equity
continued on page 2...
Relative value strategies useful
Taking advantage of "dynamic" industries
Opportunities despite hard-landing fears
Fund slated for Q1 launch
Keith Barrett, head of research at Ingenious Asset Management, asks whether outperformance in US healthcare stocks can continue or if it is time to take profits.